Obesity Medicine最新文献

{"title":"Association and inequality between socioeconomic status and the prevalence of overweight and obesity among adults aged 18 and older in Bangladesh","authors":"Sukanta Das","doi":"10.1016/j.obmed.2025.100595","DOIUrl":"10.1016/j.obmed.2025.100595","url":null,"abstract":"<div><h3>Background</h3><div>Overweight and obesity have emerged as significant public health concerns in Bangladesh. This study aims to assess the association between socioeconomic status (SES) and the prevalence of overweight and obesity while identifying socioeconomic inequalities among adults aged 18 and older in Bangladesh.</div></div><div><h3>Methods</h3><div>Using data from the Bangladesh Demographic and Health Survey (BDHS) 2017–18, this study analyzed a sample of 24,478 adults. Overweight and obesity were classified according to the World Health Organization's Body Mass Index (BMI) guidelines. SES was measured by wealth index, and its association with overweight and obesity was examined using multivariate logistic regression analysis. Socioeconomic inequality was evaluated using concentration curves and indexes.</div></div><div><h3>Results</h3><div>The overall prevalence of overweight and obesity was 31.8% and 13.4%, respectively. Even after controlling for age, gender, education, and place of residence, higher socioeconomic status was significantly associated with an increased risk of being overweight or obese. Adults in the richest wealth category were 3.2 times more likely to be overweight and 9.8 times more likely to be obese compared to those in the poorest category (p &lt; 0.01). The concentration index of 0.35 (CI: 0.33 to 0.37; <span><math><mrow><mi>p</mi></mrow></math></span> &lt; 0.01) indicated that overweight and obesity were more prevalent among wealthier adults, highlighting a pro-rich inequality.</div></div><div><h3>Conclusion</h3><div>There is a significant socioeconomic disparity in the prevalence of overweight and obesity in Bangladesh, with wealthier adults disproportionately affected. Targeted public health initiatives are needed to curb this growing epidemic, particularly among wealthier groups, to reduce obesity-related non-communicable diseases.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100595"},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143465126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between estimated glucose disposal rate, carotid intima-media thickness and cardiovascular risk prediction scales in adolescents and young adults with type 1 diabetes","authors":"David Sánchez-García,&nbsp;Eloísa Saavedra-Castillo,&nbsp;Mariela Rivas-Hernández,&nbsp;Luis Diego Maximiliano Ramos-Anthony,&nbsp;Graciela Gómez-Martínez,&nbsp;Marcelo Diaz-Sallas,&nbsp;Dania Lizet Quintanilla-Flores","doi":"10.1016/j.obmed.2025.100592","DOIUrl":"10.1016/j.obmed.2025.100592","url":null,"abstract":"<div><h3>Aims</h3><div>To analyze the correlation between estimated glucose disposal rate (eGDR), Carotid intima-media thickness (CIMT) and cardiovascular risk prediction scales in young adults with diabetes type 1 (T1D).</div></div><div><h3>Methods</h3><div>A cross-sectional, analytical, and retrospective study was conducted. Patients with T1D &gt; 15 years were included, insulin resistance (IR) was defined by eGDR &lt;8 mg/kg/min, and preclinical atherosclerosis as ≥0.54 mm of CIMT, STENO and ESC cardiovascular risk was calculated. Pearson's correlation test was used to measure the strength of association between them.</div></div><div><h3>Results</h3><div>102 patients with a median age of 19 years, HbA1c of 8.2%, diabetes duration of 8 years were included. IR was found in 50.9% of the patients and preclinical atherosclerosis in 46.1%, with a median CIMT of 0.52 mm. An inverse correlation was obtained between the eGDR and CIMT r = −0.23, p = 0.021, and STENO r = 0.33, p=&lt;0.001, CIMT was higher in the IR group 0.54 vs 0.50 mm, p = 0.047, also was associated with more microvascular complications 36.5% vs 18%, p = 0.03, and proinflammatory markers, p=&lt;0.001.</div></div><div><h3>Conclusions</h3><div>Carotid intima-media thickening is inversely associated with insulin sensitivity, the eGDR value could be used as a cardiovascular and as a enhance risk factor and could help to decide treatment in patients whit T1D.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100592"},"PeriodicalIF":0.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143471572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Murraya koenigii Linn. Modulate diabetic neuropathy via attenuation of mechanical hyperalgesia and allodynia in STZ-induced diabetic rats","authors":"Randhir Singh ,&nbsp;Shah Asma Farooq ,&nbsp;Ashi Mannan ,&nbsp;Nikhil Garg ,&nbsp;Sushma Devi ,&nbsp;Kamal Dua ,&nbsp;Thakur Gurjeet Singh","doi":"10.1016/j.obmed.2025.100593","DOIUrl":"10.1016/j.obmed.2025.100593","url":null,"abstract":"<div><h3>Introduction</h3><div>The present research aims to examine the efficacy of <em>Murraya koenigii</em> (L.) extracts in the management of diabetic peripheral neuropathy (DPN).</div></div><div><h3>Methods</h3><div>A dose of 65 mg/kg of streptozotocin (STZ) was administered intraperitoneally (i.p.) in fresh citrate buffer with a pH of 4.5 to induce diabetes 15 min after nicotinamide (230 mg/kg, ip) was administered and on 60th day development of DPN was evaluated by measuring behavioural parameters like tactile allodynia and hyperalgesia. <em>In-vitro</em> and <em>in-vivo</em> techniques were employed for estimation of oxidative stress.</div></div><div><h3>Results</h3><div>Oral administration of extracts at various doses as well as standard drug was continued up to 90th day after 60th day of STZ-NAD administration. In diabetic animals, antioxidants like as SOD and GSH levels was reduced while the level of TBARS, nitrites, TNF-α, and AGE production were significantly increased. These extracts were discovered to positively impact fasting blood sugar levels, food intake, and body weight loss management. Furthermore, research demonstrated that the extracts had positive impact on pain perception as measured by thermal and mechanical hyperalgesia in experimental rats. Studies of these extracts, both <em>in-vivo</em> and <em>in-vitro,</em> indicated their potential to reduce oxidative stress as well as hyperglycemia, which are crucial in the progression of diabetes complications.</div></div><div><h3>Conclusion</h3><div>It can be concluded that <em>Murraya koenigii</em> (L.) leaf extracts, ameliorates diabetes and diabetic peripheral neuropathy by regulating hyperglycemia and oxidative stress.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100593"},"PeriodicalIF":0.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 agonists in Type 1 diabetes – Indications and use","authors":"Panadeekarn Panjawatanan,&nbsp;Richard J. Comi","doi":"10.1016/j.obmed.2025.100591","DOIUrl":"10.1016/j.obmed.2025.100591","url":null,"abstract":"<div><h3>Objective</h3><div>Insulin therapy in Type 1 diabetes is associated with weight gain. Glucagon-like peptide 1 (GLP-1) agonists, which lower blood glucose and promote weight loss, may help reverse this trend and reduce hemoglobin A1C (A1C) levels.</div></div><div><h3>Methods</h3><div>Patients with Type 1 diabetes with concomitant GLP-1 agonists used for at least one year were included. Observed outcomes were the change in A1C, weight, and basal insulin use compared at baseline and 12 months using mixed models repeated measures.</div></div><div><h3>Results</h3><div>Forty-nine patients with weight gain were included. Prior to treatment, patients gained an average of 2.0 kg annually over three years. After 12 months of GLP-1 agonist therapy, weight significantly decreased from 97.6 kg (95% CI: 92.7–102.5) to 90.0 kg (95% CI: 84.9–95.1) (p &lt; 0.001). A1C levels also improved significantly, from 8.2% (95% CI: 7.9–8.6) to 7.6% (95% CI: 7.2–7.9) (p &lt; 0.001). Basal insulin requirements were significantly reduced.</div></div><div><h3>Conclusion</h3><div>We conclude that GLP-1 agonists effectively reverse the trend of weight gain and improve A1C levels in patients with Type 1 diabetes.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100591"},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel therapeutic approach for hormonal imbalance in polycystic ovarian syndrome; evaluating the effects of Nutrition Bio-Shield Supplement in an animal model","authors":"Mehrdad Mosadegh ,&nbsp;Yasaman Sadeghi ,&nbsp;Aref Khalkhali ,&nbsp;Yousef Erfani","doi":"10.1016/j.obmed.2025.100590","DOIUrl":"10.1016/j.obmed.2025.100590","url":null,"abstract":"<div><h3>Background</h3><div>s: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that disrupts hormone balance, leading to infertility and metabolic issues. This study evaluates the effects of a novel nutritional supplement, Nutrition Bio-Shield (NBS), on hormonal regulation in a letrozole-induced PCOS rat model.</div></div><div><h3>Methods</h3><div>Twenty-five female Wistar rats were assigned to five groups: healthy control, PCOS control, and three groups treated with varying doses of NBS (12.5 mg/kg, 25 mg/kg, and 50 mg/kg). PCOS was induced using letrozole, and NBS was administered for 21 days. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, progesterone, and estradiol were measured using radioimmunoassay.</div></div><div><h3>Results</h3><div>NBS treatment significantly improved hormone levels compared to the PCOS control group. The highest dose (50 mg/kg) effectively reduced LH and testosterone while increasing progesterone and estradiol levels (p &lt; 0.05), nearing those of the healthy controls. The 25 mg/kg dose also showed considerable improvement in hormone balance, whereas the 12.5 mg/kg dose had a moderate effect. FSH levels were notably reduced in both 50 mg/kg and 25 mg/kg groups, suggesting a dose-dependent response to NBS treatment.</div></div><div><h3>Conclusion</h3><div>NBS supplementation successfully ameliorated hormonal imbalances in a PCOS rat model, demonstrating its potential as a natural therapeutic option for managing PCOS. Further research is needed to confirm these effects in clinical settings.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100590"},"PeriodicalIF":0.0,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of safoof-e− muhazzil and orlistat on obesity and markers of obesity","authors":"Mohd Aslam ,&nbsp;Ahmad Faraz ,&nbsp;Zaki Ahmad Siddiqui ,&nbsp;Maaz Ozair ,&nbsp;Hamid Ashraf ,&nbsp;Abdul Mannan","doi":"10.1016/j.obmed.2025.100589","DOIUrl":"10.1016/j.obmed.2025.100589","url":null,"abstract":"<div><h3>Introduction</h3><div>Obesity is truly a pandemic and associated with increased risk of multiple non-communicable diseases. The available pharmacotherapy of obesity is associated with multiple limitations. We have studied the effect of sufoof e muhazzil and compared it with orlistat in non-diabetic patients with obesity.</div></div><div><h3>Material and methods</h3><div>It was an open-label, interventional prospective study including 200 patients with obesity. These patients, aged between 18 and 60 years, had a body mass index (BMI) of 25–40 kg/m². We divided them equally between the Sufoof e Muhazzil and Orlistat groups. The dose of sufoof e muhazzil was 6 gm/day, and orlistat was 120 mg twice daily for 2 months. We assessed the effect on weight, BMI, biochemical, and inflammatory markers at the onset and at the end of the study.</div></div><div><h3>Result</h3><div>The mean age, weight, BMI, and waist circumference were 37.85 years and 35.71 years, 80.7 kg and 74.9 kg, 32.7 kg/m² and 32.4 kg/m², and 113.0 cm and 112.5 cm, respectively, for the orlistat and sufoof groups. There was a significant reduction in weight, BMI, and abdominal circumference in both groups (p value &lt; 0.001 for all). Biochemical and inflammatory parameters also improved significantly in both groups. Sufoof e muhazzil use was associated with greater reductions in weight (5.8 vs 4.4 kg), BMI (2.5 vs 1.9 kg/m²) than orlistat.</div></div><div><h3>Conclusion</h3><div>Both orlistat and sufoof e muhazzil are associated with significant weight reduction and improvement in biochemical and inflammatory parameters. Both the drugs demonstrated excellent safety and tolerability.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100589"},"PeriodicalIF":0.0,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143379000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity-driven hunger: From pathophysiology to intervention","authors":"Ahmad Khusairi Azemi ,&nbsp;Yahkub Babatunde Mutalub ,&nbsp;Monsurat Abdulwahab ,&nbsp;Aida Hanum Ghulam Rasool ,&nbsp;Sagir Mustapha ,&nbsp;Siti Qusyasyiah Ahmad Suhaimi ,&nbsp;Siti Safiah Mokhtar","doi":"10.1016/j.obmed.2025.100588","DOIUrl":"10.1016/j.obmed.2025.100588","url":null,"abstract":"<div><div>Obesity is a complex metabolic disorder driven by an imbalance between energy intake and expenditure. A critical pathogenetic component of obesity is dysregulated hunger and satiety mechanisms, driven by both central and peripheral factors. This review explores the pathophysiology of obesity-induced hunger, focusing on key mechanisms involving neurohormonal signals, gut-brain communication, and the dysregulation of appetite-related pathways. It discusses the roles of hormones such as ghrelin, leptin, and insulin, as well as the influence of inflammatory processes on hunger regulation. Additionally, environmental and psychological factors contributing to food cravings and reward-driven eating are considered. The article also examines current and emerging therapeutic interventions targeting hunger and appetite control, including pharmacologic treatments, such as glucagon-like peptide-1 (GLP-1) receptor agonists, lifestyle modifications, and bariatric surgery. Novel strategies under investigation, including appetite-regulating peptides, are highlighted. Bridging the understanding of the intricate mechanisms driving obesity-related hunger with therapeutic advances provides a comprehensive framework for more effective treatment strategies to combat obesity and its associated comorbidities which will ultimately improve patient outcomes.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100588"},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of simple and specialized non-invasive tools in predicting of metabolic dysfunction-associated fatty liver disease severity and prognosis","authors":"Marjan Mokhtare ,&nbsp;Shahin Sharafeh ,&nbsp;Mohammadjavad Sotoudeheian ,&nbsp;Amir M. Sadeghian ,&nbsp;Said A. Al-Busafi","doi":"10.1016/j.obmed.2025.100582","DOIUrl":"10.1016/j.obmed.2025.100582","url":null,"abstract":"<div><h3>Objectives</h3><div>Metabolic-associated fatty liver disease (MAFLD) is a universal health concern. Detecting advanced fibrosis significantly impacts prognosis. This study designated to assess the accuracy of FIB-4, FIB-6, Agile3+, Agile4, and NAFLD fibrosis score (NFS) in predicting disease severity.</div></div><div><h3>Design and Methods</h3><div>Clinical, laboratory, and FibroScan findings of adult MAFLD patients were recorded. A fibrosis (F) score over 10 kPa indicates advanced fibrosis. We assessed the area under the receiver operating characteristic curve (AUROCC), along with the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy with various cutoff values. Reliability was analyzed with the intra-class correlation coefficient (ICC).</div></div><div><h3>Results</h3><div>Advanced fibrosis was found in 5 of 103 patients (4.85%). AUROCC values were as follows: 0.967 for Agile3+, 0.951 for FIB-6, 0.932 for NFS, 0.909 for Agile4, and 0.869 for FIB-4. The PPVs ranged from 18.18% (FIB-4) to 57.09% (NFS), followed by 75.02% (FIB-6), and 18.18% (Agile4) to 100% (Agile3+). All tools achieved acceptable NPVs above 96%. The ICC between the fibrosis score and other tools was 0.772 (95% CI: 0.696-0.834). Significant differences were noted in gamma-glutamyl transferase (p=0.039), diabetes mellitus (P=0.011), platelet count, hemoglobin A1C, alkaline phosphatase, triglycerides, fasting blood glucose, and Vitamin D levels</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100582"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological therapy for Gestational Diabetes Mellitus: A comprehensive overview","authors":"Tanu Gautam ,&nbsp;Amreen Shamsad ,&nbsp;Renu Singh ,&nbsp;S. Shabihe Raza Baqri ,&nbsp;Monisha Banerjee","doi":"10.1016/j.obmed.2025.100587","DOIUrl":"10.1016/j.obmed.2025.100587","url":null,"abstract":"<div><div>Gestational diabetes mellitus (GDM) is a prevalent metabolic condition affecting pregnant women, impairing glucose tolerance, and causing short- and long-term effects on mother, fetus, and neonate. The goal of management therapy during pregnancy is to obtain optimal glycemic control by preventing hyperglycemia and maintaining safety. The increasing prevalence of GDM worldwide is a rising concern, underscoring the need for dietary adjustments and improved detection, diagnostic and treatment strategies to overcome adverse consequences. International guidelines recommend pharmaceutical interventions for GDM when lifestyle adjustments do not attain glycemic control. Insulin is first-line treatment, but oral anti-hyperglycemic medications serve as often-used alternatives. Metformin and glyburide effectively regulate increased blood glucose in pregnancy. Metformin is preferred due to its ease of administration, reduced risk of hypoglycemia, and potential for improved long-term outcomes. Whereas glyburide is administered cautiously due to potential feto-maternal risk. In this review, the pharmaceutical alternatives for GDM have been discussed in detail, along with pharmacology and pharmacokinetics. The effects of metabolic and glycemic control on feto-maternal morbidity have also been elaborated, along with efficacy as well as side effects and long-term outcomes. However, their long-term safety profiles and fetal exposure remain unclear. By focusing on this research gap, we can explore effective management therapy by evaluating feto-maternal long-term outcomes through follow-up studies, comparing efficacy of pharmacological interventions, pharmacogenomics, digital health technologies, emerging pharmaceutical alternatives (GLP-1-Ra &amp; SGLT-2 inhibitors), and personalized medicine. By incorporating these advancements into clinical practice by healthcare professionals, the risk of adverse effects may decrease to improve health and well-being.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100587"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Betula alnoides bark: Insilico and preclinical insights into its antioxidant and lipid-lowering effects in hypercholesterolemia","authors":"Shahbaz Khan ,&nbsp;Alka Lohani ,&nbsp;Prashant Tiwari ,&nbsp;Sunil Kumar Kadiri","doi":"10.1016/j.obmed.2025.100583","DOIUrl":"10.1016/j.obmed.2025.100583","url":null,"abstract":"<div><h3>Aim</h3><div>Hyperlipidemia characterized by elevated cholesterol levels and formation of Reactive Oxygen Species (ROS) is a critical risk factor for coronary heart diseases. In traditional Indian Ayurveda and herbal medicine, various parts of <em>Betula alnoides</em> are reputed for their therapeutic uses. The main aim of this study is to explore the hypolipidemic and antioxidant effects of <em>Betula alnoides</em> bark extracts (petroleum ether and ethyl acetate) in rats with induced hypercholesterolemia.</div></div><div><h3>Methods</h3><div>Soxhlet extraction method was used to extract <em>Betula alnoides</em> bark powder, utilizing petroleum ether and ethyl acetate as solvents and both the extracts underwent phytochemical screening to identify a range of phytoconstituents. The acute oral toxicity was evaluated on male albino rats, adhering to OECD guideline No. 420. DPPH and nitric oxide scavenging assay was used to determine antioxidant capacity of bark extracts. Hypolipidemic activity was evaluated by inducing hyperlipidemia through a high-fat diet and measuring serum biochemical markers like total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides.</div></div><div><h3>Results</h3><div>The extraction yields were found to be 1.4% ± 0.65% for the petroleum ether extract and 3.2% ± 0.80% for the ethyl acetate extract. In the acute toxicity study, it was found that the bark extracts showed no signs of toxicity. The findings indicated that the DPPH/Nitric oxide free radical scavenging capacity of <em>Betula alnoides</em> bark extracts increased with higher concentrations. When compared to the petroleum ether bark extract, the ethyl acetate bark extract showed a noticeably better antioxidant capacity. Both petroleum ether and ethyl acetate extracts (50 mg/kg and 100 mg/kg) and fenofibrate (65 mg/kg), exhibited significant hypolipidemic effects.</div></div><div><h3>Conclusion</h3><div>The ethyl acetate extract demonstrated superior hypolipidemic activity compared to the petroleum ether extract. Lupeol binds strongly to SOD, SGLT2, and APOE proteins, showing significant docking scores and engaging multiple amino acids through various stabilizing interactions. These findings suggest that <em>Betula alnoides</em> bark extracts possess promising antioxidant and anti-hyperlipidemic properties.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100583"},"PeriodicalIF":0.0,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}